Notícias
Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.
<body><p>STORY: Big pharma is receiving pushback from European capitals on drug pricing. </p><p>So they’re turning to a playbook that brought them success in the UK.</p><p>Making threats to pull investment plans to pressure policymakers. </p><p>The industry notched a win when the British government agreed to increase medicine spending as part of a broader deal to avoid U.S.-imposed tariffs. </p><p>The latest nation to face pressure is Germany, which has been debating legislation to tighten spending on medicines. </p><p>A Reuters European Pharma correspondent Maggie Fick said pressure in the last week has ramped up. </p><p>"The CEO of Pfizer wrote a letter to the German chancellor warning that their future investments in the country may be at risk over these proposed changes to pricing laws."</p><p>Meanwhile, AstraZeneca warned that it may not launch new medicines in Germany if these changes go ahead.</p><p>Earlier in June, Eli Lilly announced it would halve a planned $2.7 billion investment, also citing the proposed legislation. </p><p>This bid to cap costs has centered Germany in a broader tussle between drugmakers and European governments that began several months ago.</p><p>That tension has been sharpened by the impact on Europe of U.S. President Donald Trump's pricing push.</p><p>This aims to tie prescription medicine prices in the lucrative U.S. market to lower prices elsewhere, including in Europe.</p><p>Major drugmakers have struck deals with the White House to lower drug costs in exchange for tariff exemptions, adding to pressure for increasing prices elsewhere.</p></body>
Eli Lilly and Co (NYSE:LLY) is one of billionaire Ken Fisher’s top high growth stock picks. In the past month, Lilly shares have gained more than 18%. The shares have soared almost 50% over the past year. On June 6, Eli Lilly and Co (NYSE:LLY) presented results from late-stage trials of its weight-loss drug candidate, […]
CEO Doustdar expects to submit oral Wegovy for Chinese regulatory approval in "a few months"
Eli Lilly (LLY) became the first pharmaceutical company to cross a $1 trillion market valuation in November last year, carried largely by its highly lucrative obesity and diabetes medications, such as Mounjaro and Zepbound. Now the same demand that built that fortune is creating friction with the ...
Healthcare stocks edged higher Tuesday afternoon, with the NYSE Healthcare Index and the State Stree
These two healthcare leaders have a long history of competing against one another.
Eli Lilly is acquiring Austin-based 4E Therapeutics, the developer of non-addictive painkillers, for an undisclosed amount.
Gain insight on Roche, Zealand Pharma and more in the latest Market Talks covering the health care sector.
The European stock markets were modestly higher in Tuesday trading as the markets reacted positively
Eli Lilly (NYSE:LLY) is acquiring 4E Therapeutics, adding MNK inhibitor candidates aimed at non opioid chronic pain treatment. The deal expands Lilly's neuroscience pipeline beyond its existing focus on metabolic and diabetes therapies. Jaypirca has reached a key clinical milestone in the Phase 3 BRUIN CLL-322 trial in relapsed or refractory chronic lymphocytic leukemia when used with venetoclax and rituximab. These developments represent fresh, material updates for Eli Lilly that relate...
AZN shares fell after a camizestrant setback, but blockbuster drugs, oncology growth and a deep pipeline support long-term targets.
Explore how portfolio concentration and stock count set these healthcare ETFs apart, impacting risk and diversification for investors seeking sector exposure.
The move could expand Novo's reach in a key obesity-drug market.
It’s the latest in a string of deals for Lilly, which has sunk more than $18 billion into acquisitions over the past few years.
Eli Lilly's recent GLP-2 deal with Hanmi Pharm is another step in the drugmaker’s quest to grow its GLP franchise beyond weight loss and deepen its push into gastrointestinal disease.
Novo Nordisk (NVO) plans to apply for Chinese regulatory approval of its oral weight-loss drug, Wego
Eli Lilly has experienced robust growth, but investors may be thinking twice about the stock due to its high valuation.
Led by top holdings like Popular, East West Bancorp and Zions, KRE ETF is in buy range as the financial ETF flashes signs of strength.
NVO stock jumps 7% in a week on U.K. approval of oral Wegovy and positive commercial updates, but competition and 2026 pressure cloud near-term outlook.
Acquired through its purchase of Ajax, the drug showed encouraging effects in patients with hard-to-treat myelofibrosis. To analysts, such results could lead to competition for Incyte’s Jakafi.
Hyderabad-based Electronics Mart India is looking to diversify away from the technology hub as concerns grow that potential AI-triggered job losses could hurt consumer spending, a top executive said. The retailer gets about 60% of its revenue from Hyderabad, which hosts offices of global companies such as JPMorgan Chase and Eli Lilly, and Indian IT majors Wipro and Infosys. Around a fifth of its stores in Hyderabad are located in neighbourhoods where the majority of the residents are software employees.
Eli Lilly (NYSE:LLY) reported Phase 1 data for AJ1-11095, a first-in-class type II JAK2 inhibitor, in myelofibrosis patients. The AJX-101 study focused on individuals whose disease continued after prior type I JAK2 inhibitor treatment. Early results showed encouraging safety findings and clinical activity in this difficult to treat group. Eli Lilly is widely associated with its obesity drug portfolio, but the AJ1-11095 update highlights a broader pipeline that includes hematology and...
Eli Lilly is winning the GLP-1 race right now, but it isn't resting on its laurels.
The National Bureau of Economic Research paper's lead author hopes putting a dollar value on the benefits of GLP-1s will lead to better access
With a profit margin of 34.99% and net income of $20.64 billion (FY25), Eli Lilly and Company (NYSE:LLY) ranks among the most profitable blue chip stocks to buy according to hedge funds. Meanwhile, analysts see 9.20% upside for the stock. That outlook comes during a particularly active stretch of regulatory and clinical news for Lilly’s […]
We recently published Jim Cramer Didn’t Hold Back On SpaceX’s IPO & Discussed These 12 Stocks. Eli Lilly and Company (NYSE:LLY) is one of the stocks discussed by Jim Cramer. Healthcare and pharmaceutical giant Eli Lilly and Company (NYSE:LLY) is one of Jim Cramer’s favorite stocks. Throughout 2025, the CNBC TV regularly praised the firm […]
In the closing of the recent trading day, Eli Lilly (LLY) stood at $1, denoting a -2.41% move from the preceding trading day.
While the market fixates on the STELARA patent cliff, the rest of the business is quietly accelerating. Excluding the legacy drug, Johnson & Johnson (JNJ) grew in double digits for the quarter. The Innovative Medicine segment absorbed a massive 920 basis point headwind from STELARA, yet still posted 7.4% growth. This is not a company treading water, but a portfolio already hitting its next stride.